GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
- Country
- United Kingdom
- Type
- Beneficiary
- Website
- www.gsk.com
- Grants received
- 53
Funding record
- 53 grants on record
- €2,550,777.33 awarded in total
- 2008–2026 years covered
This total adds up only the grants our sources publish. It is not the total funding this organisation has received.
Programmes
35 further grants are on record without a programme named by the source, or under a programme outside the largest shown here.
Frequent partners
Organisations funded alongside this one on two or more projects. Sharing a single project does not count. Some projects have as many as 195 participants, and appearing on the same list once is not a working relationship.
- NOVARTIS PHARMA AG
- JANSSEN PHARMACEUTICA NV
- BAYER AKTIENGESELLSCHAFT
- NOVO NORDISK A/S
- ELI LILLY AND COMPANY LTD
- UCB BIOPHARMA
- BOEHRINGER INGELHEIM INTERNATIONALGMBH
- ASTRAZENECA AB
Calls from this organisation
No published calls from this organisation.
Grants received
- Driving Sustainable Innovation to Minimise PFAS in European Healthcare
- Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins
- FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE
- GUIDE-AI – Guiding your treatment with current evidence
- Patient Relevant Osteoarthritis endpoints using Big data Evaluation
- Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG
- Research in Europe and Diversity Inclusion
- Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)
- Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing
- Reducing Non-Human Primates in Non-Clinical Safety Assessment: The European Initiative on Minipig and Micropig Models
- Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research
- Prioritisation and Risk Evaluation of Medicines in the EnviRonment
- Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
- Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
- PharmaLedger
Data source
© European Union, 2026. Source: CORDIS. Reused under Commission Decision 2011/833/EU — CC BY 4.0.
We collected this from the source on .
Personal data of natural persons has been dissociated by quiescence.eu.
This service is not affiliated with, sponsored or endorsed by the data publishers.